Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefazolin with or without postoperative cefuroxime for prophylaxis in type 1 tympanoplasty
IRCT20260915071075N1Phase 3Recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Sep 2026
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cefazolin and cefuroxime in tympanic membrane perforation (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Incidence of surgical site infection, Graft success and 4 more. Started Sep 2026; status: recruiting.
02
Drugs
cefazolincefuroxime
03
Conditions
tympanic membrane perforation
Beyond the preview
Go deeper on IRCT20260915071075N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260915071075N1.